Skip to main content
Clinical Trials/NCT01620853
NCT01620853
Completed
Not Applicable

Concordance Study for Detection of Chromosomal Aberrations Using FISH (ALK Test)in Non-small Cell Lung Cancer (NSCLC)

Applied Spectral Imaging Ltd.1 site in 1 country1 target enrollmentMay 2012

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Non-small Cell Lung Cancer (NSCLC)
Sponsor
Applied Spectral Imaging Ltd.
Enrollment
1
Locations
1
Primary Endpoint
IVD study
Status
Completed
Last Updated
11 years ago

Overview

Brief Summary

The purpose of the study is the identification of chromosomal aberrations in non-small cell lung cancer (NSCLC) .

The imaging system is intended for diagnostic use as an aid to the pathologist in the detection, counting and classifying ALK FISH stained lung samples.

Detailed Description

The ALK Break Apart FISH test detects chromosomal aberrations via fluorescence in situ hybridization (FISH) in formalin-fixed paraffin-embedded (FFPE) non-small cell lung cancer (NSCLC) tissue specimens. The FDA approved ALK kit is designed to detect rearrangements involving the ALK gene (2p23). Results from the ALK Kit are intended for use, in conjunction with and not in lieu of current standard diagnostic procedures, as an aid for the pathologist in the identification of patients eligible for treatment with XALKORI® (crizotinib).

Registry
clinicaltrials.gov
Start Date
May 2012
End Date
January 2013
Last Updated
11 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Well stained slides with bright FISH signals

Exclusion Criteria

  • Very old slides that were already bleached

Outcomes

Primary Outcomes

IVD study

Time Frame: 1 Day

Study Sites (1)

Loading locations...

Similar Trials